The drug "Tagista" instructions for use refers to the pharmacotherapeutic group of histamine. The international non-proprietary name is Betagistin.
The active substance of the drug is betahistine dihydrochloride. Additional components - microcrystalline cellulose, collidone 25 (povidone), citric acid, potato starch, colloidal silicon dioxide (aerosil), magnesium stearate, talc.
The drug "Tagista" (instructions for use informs) is available in the form of tablets of a cylindrical shape, having a white or white with a cream tint color.
The drug is adsorbed quite actively. It is characterized by a low bond with blood proteins. After three hours, the maximum concentration of the drug is achieved. The considered pharmaceutical agent is excreted by the kidneys in the form of a metabolite (almost completely) during the day. The elimination half-life is usually three to four hours.
The drug is indicated for use in the following cases:
- for the treatment and prevention of dizziness (vestibular) of a particular genesis;
- with syndromes such as headache, nausea, vomiting, progressive hearing impairment, tinnitus, headaches, dizziness.
It is not recommended to use this tool with hypersensitivity to one or more components of the drug, as well as if the patient's age is less than eighteen years (due to lack of necessary research data). Do not prescribe medication during pregnancy and lactation, since information on its safety for this category of people is not available.
The drug "Tagista", the instructions for use which describe in detail all the indications and contraindications for its use, are prescribed with extreme caution in case of gastric ulcer (and / or duodenal ulcer), pheochromocytoma and bronchial asthma. The indicated category of persons throughout the entire course of treatment should be under the constant supervision of a specialist.
The drug "Tagista". Instructions for use
For tablets, eight milligrams - 1-2 three times a day, sixteen - 0.5-1 with the same frequency, twenty-four milligrams - one tablet twice a day.
As a rule, an improvement is observed already from the first days of treatment, and a stable therapeutic effect occurs after two weeks from the start of the drug. The course of use of the medication is long, the terms are determined individually by the attending physician.
Against the background of taking the drug “Tagista” (the instruction informs about it), side effects such as digestive system disorders, allergic reactions (urticaria, rash, itching) are possible, and in rare cases, Quincke edema occurs.
An overdose of the drug is accompanied by convulsions, vomiting, nausea. In addition to symptomatic treatment, gastric lavage and adsorbent (activated carbon) are indicated.
Cases of interaction or incompatibility with other drugs have not been recorded.
The period during which the drug is suitable for use is thirty-six months from the date indicated on the package.
Betahistine dihydrochloride (the main active ingredient) does not have a sedative effect, therefore, does not affect the ability to drive vehicles. Also during the treatment period it is not forbidden to conduct activities that require a quick psychomotor response.
The optimal temperature for storing the drug is + 22-25 degrees Celsius.
The pharmaceutical agent "Tagista", the description of which was given above, can be purchased in pharmacies only with a doctor's prescription.